The British Pharmaceutical AstraZeneca and the University of Oxford interrupt the advanced tests with a possible coronavirus vaccine for safety reasons, reports the health news website Stat News. The potential vaccine may have caused undesirable side effects in a subject. The European Commission and the Netherlands have made a deal with AstraZeneca for the vaccine developed by the pharmaceutical company with the University of Oxford.
“Standard assessment procedures have led to an interruption of vaccinations to assess the safety data,” says a spokesman for AstraZeneca in a statement. He says it’s a routine decision.
What undesirable effect has occurred in the subject and when it has occurred is not known. The subject is expected to recover.
An insider says that the tests have been shut down because of a”high degree of caution”. A second insider, who does not wish to be named and named, argues that the finding that led to the interruption affects the tests carried out by AstraZeneca, which have yet to be carried out, and those of other pharmacists carrying out vaccine trials.
A spokesman for AstraZeneca says that illness can always occur in large-scale trials. Individual cases which arise must then be examined carefully, according to the spokesman.
Nine major vaccine producers from Europe and the United States solemnly promised on Tuesday that they would not lower their normal safety standards, despite the great pressure that exists to quickly develop an effective vaccine. AstraZeneca also made that promise.
The tests on the so-called Oxford Vaccine, which are in the third phase, are currently mainly carried out in the United States. The test in which the undesirable side effects would have occurred took place in the United Kingdom.